Mysema 1 Injection 1 mg/.5 ml

Mysema 1 Injection contains semaglutide, a GLP-1 receptor agonist given by injection. It is used under medical supervision to help manage type 2 diabetes and, in selected patients, chronic weight management alongside diet and lifestyle measures.

Mysema 1 Injection 1 mg/.5 ml injection from Drug International Ltd., Gopalpur contains Semaglutide, a GLP-1 receptor agonist. Doctors prescribe it for adults with type 2 diabetes, and in carefully selected patients for medically supervised weight management. It is a powerful prescription medicine — not a casual slimming product to be bought and used on one's own.

Semaglutide copies a natural gut hormone called GLP-1. It prompts the pancreas to release insulin when blood sugar is high, reduces the sugar-raising hormone glucagon, slows the emptying of the stomach and acts on appetite centres in the brain. The result is lower blood sugar, less hunger and gradual weight loss, and in studies it also protected the heart in people with type 2 diabetes.

Mysema 1 Injection may be prescribed by a doctor for:

• Type 2 diabetes in adults, with diet and exercise, when other medicines are not enough or when weight and heart risk also need attention
• Chronic weight management in adults with obesity, or overweight with weight-related conditions such as diabetes, high blood pressure or sleep apnoea — always combined with diet and physical activity and only under medical supervision

It is not used for type 1 diabetes or diabetic ketoacidosis, and it is not meant for cosmetic slimming in people of normal weight. The decision to start, the goal of treatment and the target dose all rest with your doctor.

ChamberBD shows dosing only from the approved product label, with its source named, and no label is on file for Mysema 1 Injection 1 mg/.5 ml. Use the dose your doctor prescribed and the instructions in the pack leaflet.

The most common side effects are digestive, especially when starting or increasing the dose:

• Nausea, vomiting, diarrhoea or constipation, indigestion, burping and reduced appetite — these usually ease over weeks
• Tiredness, headache or dizziness
• Low blood sugar when combined with insulin or a sulfonylurea

Less common but important: dehydration from repeated vomiting (which can strain the kidneys), gallbladder problems (pain in the right upper abdomen, sometimes with fever or yellowing), and rarely pancreatitis — severe persistent stomach pain radiating to the back. Rapid sugar improvement can temporarily worsen diabetic eye disease, so report vision changes. A lump in the neck, hoarseness or trouble swallowing should also be reported promptly.

Key precautions with Mysema 1 Injection:

• Do not use it as a casual slimming drug. It must be prescribed after proper medical assessment; buying it informally or using someone else's pen for quick weight loss is dangerous.
• To ease nausea, eat smaller meals slowly, avoid very fatty or spicy food and stop eating when full; drink enough fluids, especially if vomiting occurs.
• Tell your doctor about any history of pancreatitis, gallstones, thyroid problems or diabetic eye disease (retinopathy) — extra monitoring may be needed.
• If you plan pregnancy, tell your doctor well in advance; the medicine is usually stopped about two months before trying to conceive.

Never stop or restart Mysema 1 Injection on your own — your doctor manages the schedule.

Tell your doctor and pharmacist about everything you take. Important interactions of Mysema 1 Injection:

• Insulin and sulfonylureas (e.g. glimepiride, gliclazide) — combined use raises the risk of low blood sugar; their doses are often reduced.
• Because Semaglutide slows stomach emptying, it can change how quickly some oral medicines are absorbed — medicines with narrow margins, such as levothyroxine or warfarin, may need closer monitoring.
• If you use the oral tablet, take it alone on an empty stomach and wait at least 30 minutes before any other medicine, including thyroid tablets and antacids.

Also mention any herbal weight-loss products, as combining them is unsafe and unnecessary.

Do not use Mysema 1 Injection if:

• You are allergic to Semaglutide or any other ingredient
• You or a close family member has had medullary thyroid carcinoma, or you have the rare syndrome MEN 2 (multiple endocrine neoplasia type 2)
• You are pregnant, trying to conceive or breastfeeding

Mysema 1 Injection is not a treatment for type 1 diabetes or diabetic ketoacidosis. It should be used with great caution, and only on specialist advice, in people with previous pancreatitis or severe stomach and bowel disease. If a severe allergic reaction occurs — swelling of the face or throat, difficulty breathing — stop the medicine and seek emergency care.

Mysema 1 Injection must not be used during pregnancy — animal studies suggest possible harm to the baby, and weight loss itself is unwanted in pregnancy. Because semaglutide stays in the body for a long time, doctors usually advise stopping it about two months before trying to conceive; effective contraception is recommended during treatment. If you become pregnant while using it, stop the medicine and contact your doctor promptly so diabetes care can be switched, usually to insulin.

It is not known whether semaglutide passes into human breast milk, so it is not recommended while breastfeeding. Ask your doctor for a suitable alternative during this period.

Store as printed on the pack and keep out of the reach of children.